; and (2) by adding at the end the following new clauses: (ii) Prices negotiated with pharmacy at point-of-sale (I) Temporary freeze on dir payments Subject to subclause (IV), for plan years beginning on or after January 1, 2021, and before January 1, 2026, negotiated prices for covered part D drugs described in clause (i) provided under all phases of coverage under a prescription drug plan, including all contingent and noncontingent concessions, payments, and fees negotiated with the pharmacy dispensing such drug, shall be provided at the point-of-sale of such drug. For purposes of the preceding sentence, such negotiated price shall not include any incentive payments paid to pharmacies. (II) Application of price concessions For plan years beginning on or after January 1, 2026, the Secretary shall promulgate regulations prohibiting the application of any pharmacy price concessions that are not based on quality measures established or approved by the Secretary under subclause (III). (III) Standard pharmacy quality measures Subject to subclause (I), not later than January 1, 2021, the Secretary shall establish or approve standard quality measures for use in the application of pharmacy price concessions and incentive payments with respect to payment for covered part D drugs dispensed by a pharmacy. Such measures shall be— (aa) focused on improving patient health outcomes; (bb) standardized across PDP sponsors; (cc) pharmacy-specific in application; (dd) relevant to the type of pharmacy concerned (such as specialty pharmacies), taking into account the items and services furnished by the pharmacy and the patient population served by the pharmacy; (ee) applied only when relevant to the specific drug (or drug class of such drug) being furnished by the pharmacy or when relevant to management of the condition for which such drug has been prescribed